Potassium chloride

Generic Medicine Info
Potassium: Should be taken with food.
Potassium chloride: Should be taken with food.
Hyperkalaemia, hyperchloraemia, predisposing conditions for hyperkalaemia (e.g. acute dehydration, systemic acidosis, extensive burns or tissue injury); adrenal insufficiency (e.g. Addison's disease), heat cramps, renal failure, renal impairment with oliguria, anuria or azotaemia; plasma-K concentration >5 mEq/L. Tab/cap: Structural, pathological (e.g. diabetic gastroparesis), and/or pharmacologic (e.g. use of anticholinergics) cause for arrest or delay in gastrointestinal passage. Severe renal impairment. Concomitant use with K-sparing diuretics.
Special Precautions
Patient with acid-base alterations or correction; CV disease (e.g. heart failure, cardiac arrhythmias, atrioventricular block), cirrhosis. Avoid extravasation (IV). Hepatic and mild to moderate renal impairment. Children and elderly. Pregnancy and lactation. Monitoring Parameters Closely monitor serum K concentrations and other electrolyte levels (e.g. serum Ca, chloride, Mg, phosphate, Na), acid-base balance, renal function, IV infusion rate, cardiac, clinical and fluid status prior to initiation and regularly during treatment. Perform ECG monitoring regularly.
Adverse Reactions
Significant: IV infusion: Hypersensitivity/infusion reactions (e.g. anaphylaxis, chills), hyponatraemia. Oral: Gastrointestinal irritation (oral solution); ulcerative and/or stenotic lesions of the gastrointestinal tract (tab/cap). Gastrointestinal disorders: Nausea, vomiting, flatulence, abdominal pain or discomfort, diarrhoea; gastrointestinal haemorrhage, ulceration, perforation (tab/cap). Metabolism and nutrition disorders: Hypervolaemia. Injury, poisoning and procedural complications: Inj site reactions (e.g. pain, phlebitis, venous thrombosis).
Potentially Fatal: Hyperkalaemia.
Drug Interactions
May increase the risk of hyperkalaemia with ACE inhibitors, angiotensin II receptor antagonists, ciclosporin, aliskiren. May enhance the antiarrhythmic effects of quinidine. May cause K retention with NSAIDs. May enhance the ulcerogenic effect of solid oral dosage forms of K chloride with anticholinergic agents. May cause further decrease in plasma K concentration with glucose infusion (IV).
CIMS Class
ATC Classification
A12BA01 - potassium chloride ; Belongs to the class of potassium-containing preparations. Used as dietary supplements.
B05XA01 - potassium chloride ; Belongs to the class of electrolyte solutions used in I.V. solutions.
Disclaimer: This information is independently developed by CIMS based on potassium chloride from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in